



CS/NSE&BSE/2018-19
April 24, 2018

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN – EQ

Stock Code: 530239

Dear Sir/Madam,


Sub: USFDA Inspection

.....
We would like to inform our shareholders through exchanges about the information appeared in media about FDA inspection in our Pashamylaram, Medak unit during Feb 2018.

US FDA during the inspection observed that there are procedures that followed on certain aspects are deficient in nature. Since these observations are procedural in nature, we have already revised our standard operating procedures (SOP's) as a corrective action and trained employees in the new SOP's thus creating new policies for the companies' quality systems and operating systems and submitted documented proofs of all these remedial measures to FDA well in time.

This is for your information and record please.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor | Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com